Senti Biosciences Holdings (SNTI) Change in Receivables (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Change in Receivables of $213000.0 for Q4 2025, up 150.59% year-over-year from $85000.0 in Q4 2024, and up 111.05% quarter-over-quarter from -$1.9 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Change in Receivables (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Change in Receivables history runs 5 years deep, the most recent figure standing at $213000.0 for Q4 2025.
- In Q4 2025, Change in Receivables rose 150.59% year-over-year to $213000.0; the TTM figure through Dec 2025 stood at $164000.0 (up 248.94% YoY), while the FY2025 annual figure was $164000.0, up 248.94% from the prior year.
- Change in Receivables for Q4 2025 stood at $213000.0, up from -$1.9 million in the prior quarter.
- The five-year high for Change in Receivables was $1.9 million in Q4 2023, with the low at -$1.9 million in Q3 2025.
- The 5-year median for Change in Receivables is $44500.0 (2021), against an average of $114250.0.
- Peak annual rise in Change in Receivables reached 3774.36% in 2025, while the deepest fall reached 5041.03% in 2025.
- Senti Biosciences Holdings' Change in Receivables stood at $50000.0 in 2021, then soared by 162.0% to $131000.0 in 2022, then jumped by 1384.73% to $1.9 million in 2023, then sank by 95.63% to $85000.0 in 2024, then soared by 150.59% to $213000.0 in 2025.
- Business Quant data shows SNTI's Change in Receivables at $213000.0 in Q4 2025, -$1.9 million in Q3 2025, and $1.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 213,000.00 |
| Dec 31, 2025 | 213,000.00 |
| Sep 30, 2025 | -1.93 Mn |
| Sep 30, 2025 | -1.93 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 445,000.00 |
| Mar 31, 2025 | 445,000.00 |
| Dec 31, 2024 | 85,000.00 |
| Dec 31, 2024 | 85,000.00 |
| Sep 30, 2024 | 39,000.00 |
| Sep 30, 2024 | 39,000.00 |
| Jun 30, 2024 | -39,000.00 |
| Jun 30, 2024 | -39,000.00 |
| Mar 31, 2024 | -38,000.00 |
| Mar 31, 2024 | -38,000.00 |
| Dec 31, 2023 | 1.95 Mn |
| Dec 31, 2023 | 1.95 Mn |
| Sep 30, 2023 | -445,000.00 |
| Sep 30, 2023 | -445,000.00 |